ArticleJournal of community hospital internal medicine perspectives2025
Elevated Creatine Kinase as a Marker for Aggressive GI Malignancy.
Article in Journal of community hospital internal medicine perspectives, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Klatskin tumor is a rare and aggressive biliary malignancy with a poor prognosis. We present a 72-year-old male with a history of COPD and severe non-ischemic cardiomyopathy who presented with jaundice, pruritus, and fatigue. Laboratory findings revealed marked hyperbilirubinemia and elevated liver enzymes, along with significantly increased creatine kinase (CK). Imaging studies and ERCP confirmed the diagnosis of perihilar cholangiocarcinoma, Bismuth class III, with adenocarcinoma pathology. Despite palliative stent placement, the patient's bilirubin levels remained elevated, and CK peaked at 45,000 units/L. Due to his advanced disease and comorbidities, he was not a candidate for surgical or systemic therapy and was transitioned to home hospice. This case highlights the diagnostic and therapeutic challenges in managing Klatskin tumors and the importance of recognizing significant elevation in CK, which in the absence of signs of muscle breakdown/pain may hypothetically correlate with aggressive forms of gastrointestinal malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.